Neonatal Fc Receptor Blocker [EPC]

4387 reported adverse events

Drugs of this class: EFGARTIGIMOD ALFA EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT) ROZANOLIXIZUMAB

These side effects are most commonly reported by patients taking drugs of the Neonatal Fc Receptor Blocker [EPC] class:

# Side effect Count
0 MYASTHENIA GRAVIS 841
1 MYASTHENIA GRAVIS CRISIS 471
2 FATIGUE 453
3 DYSPNOEA 318
4 ASTHENIA 296
5 FALL 251
6 DRUG INEFFECTIVE 245
7 MUSCULAR WEAKNESS 232
8 URINARY TRACT INFECTION 231
9 HEADACHE 209
See all common reactions for Neonatal Fc Receptor Blocker [EPC]

Drugs of the Neonatal Fc Receptor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 THYMECTOMY 36 0.4091
1 MYASTHENIA GRAVIS CRISIS 471 0.3176
2 VENOUS ANGIOPLASTY 3 0.2500
3 THYMOMA MALIGNANT RECURRENT 3 0.2000
4 PROCEDURAL HEADACHE 74 0.1805
5 MYASTHENIA GRAVIS 841 0.1040
6 ACTIVITIES OF DAILY LIVING ASSESSMENT 2 0.1000
7 BULBAR PALSY 16 0.0578
8 THYMOMA 19 0.0526
9 GASTROSTOMY TUBE REMOVAL 2 0.0400
See all enriched reactions for Neonatal Fc Receptor Blocker [EPC]